Slingshot members are tracking this event:

Jardiance (Empagliflozin) Consistently Reduced The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes Regardless Of The Type Of Cardiovascular Disease At Baseline

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LLY Community voting in process

Additional Information

Additional Relevant Details
"Cardiovascular disease is two to four times more common in people with type 2 diabetes and is an umbrella term consisting of several different vascular outcomes, including heart attack, heart failure, peripheral vascular disease and stroke," said lead investigator of the trial Bernard Zinman, M.D., director, Diabetes Centre, Mount Sinai Hospital, Toronto; senior scientist, Lunenfeld Tanenbaum Research Institute, and professor of medicine,University of Toronto. "Since approximately two out of three deaths in people with type 2 diabetes in the U.S. are attributed to cardiovascular causes, we need diabetes therapies that help reduce this complication in individuals who have an underlying cardiovascular issue."  
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 13, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Jardiance, Empagliflozin, Diabetes